Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1746-1596

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N ; volume:11 ; number:1 ; day:18 ; month:5 ; year:2016 ; pages:1-9 ; date:12.2016
Diagnostic pathology ; 11, Heft 1 (18.5.2016), 1-9, 12.2016

Creator: Smith, Jacquelyn

Contributor: Robida, Mark D.
Acosta, Krista
Vennapusa, Bharathi
Mistry, Amita
Martin, Greg
Yates, Alton
Hnatyszyn, H. James
SpringerLink (Online service)

DOI: 10.1186/s13000-016-0494-2

URN: urn:nbn:de:1111-201605196819

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:51 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Smith, Jacquelyn
Robida, Mark D.
Acosta, Krista
Vennapusa, Bharathi
Mistry, Amita
Martin, Greg
Yates, Alton
Hnatyszyn, H. James
SpringerLink (Online service)

Other Objects (12)

PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28–8 and E1L3N)

Performance of different diagnostic PD-L1 clones in head and neck squamous cell carcinoma

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

PD-L1 degradation pathway and immunotherapy for cancer

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Expression of PD-L1 clones (22C3 and 28-8) in hepatocellular carcinoma: a tertiary cancer care hospital experience

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28–8 and E1L3N)

Performance of different diagnostic PD-L1 clones in head and neck squamous cell carcinoma

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

PD-L1 degradation pathway and immunotherapy for cancer

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Expression of PD-L1 clones (22C3 and 28-8) in hepatocellular carcinoma: a tertiary cancer care hospital experience

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28–8 and E1L3N)

Performance of different diagnostic PD-L1 clones in head and neck squamous cell carcinoma

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

PD-L1 degradation pathway and immunotherapy for cancer

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Expression of PD-L1 clones (22C3 and 28-8) in hepatocellular carcinoma: a tertiary cancer care hospital experience

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28–8 and E1L3N)

Performance of different diagnostic PD-L1 clones in head and neck squamous cell carcinoma

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

PD-L1 degradation pathway and immunotherapy for cancer

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Expression of PD-L1 clones (22C3 and 28-8) in hepatocellular carcinoma: a tertiary cancer care hospital experience

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28–8 and E1L3N)

Performance of different diagnostic PD-L1 clones in head and neck squamous cell carcinoma

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

PD-L1 degradation pathway and immunotherapy for cancer

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Expression of PD-L1 clones (22C3 and 28-8) in hepatocellular carcinoma: a tertiary cancer care hospital experience

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28–8 and E1L3N)

Performance of different diagnostic PD-L1 clones in head and neck squamous cell carcinoma

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

PD-L1 degradation pathway and immunotherapy for cancer

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Expression of PD-L1 clones (22C3 and 28-8) in hepatocellular carcinoma: a tertiary cancer care hospital experience

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Related objects

Reset password